ContextLogic (OTCMKTS:LOGC)

ContextLogic (formerly the parent company of the e-commerce marketplace Wish) transformed from a struggling online retailer into a publicly traded business-ownership and acquisition platform. 

• https://www.contextlogic.com/

Key Milestones and Changes

Sale of Wish: In early 2024, ContextLogic sold its core Wish e-commerce operations for $173 million. 
Preservation of Tax Assets: Instead of liquidating, the company pivoted to preserve roughly $2.9 billion in net operating losses (NOLs) to shield future corporate profits from taxes. 
Delisting from Nasdaq: The company voluntarily delisted from Nasdaq in mid-2025 and moved to trade over-the-counter on the OTCQB market under the ticker symbol LOGC. 
Corporate Reorganization: In August 2025, ContextLogic completed a corporate restructuring, making ContextLogic Inc. a subsidiary of ContextLogic Holdings Inc. 
Acquisition of US Salt: In early 2026, ContextLogic completed a $907.5 million acquisition of US Salt in partnership with Abrams Capital and BC Partners Credit, shifting its primary business focus into the production and distribution of evaporated salt. 
Current Status: It trades on the OTC market as ContextLogic Holdings Inc.

OrthoPediatrics (KIDS) reported earnings on Tue 27 Oct 26 (a/h)

OrthoPediatrics Corp. is an orthopedic company, which engages in the design, development, and marketing of anatomically appropriate implants and devices for children with orthopedic conditions. It offers products relating to trauma and deformity, scoliosis, and sports medicine and other procedures. 

• Sector: Healthcare
• Industry: Medical Devices
• Full Time Employees: 602
• Founded by Erin Springer Yount and Nick A. Deeter in 2006 
• Headquartered in Warsaw, Indiana
• https://www.orthopediatrics.com

IPO Key Details

• IPO Date: October 12, 2017

• Offer Price: $13.00 per share

 

 

 

OrthoPediatrics posts record Q3 2026 revenue $72.7M (+19% YoY), raises 2026 revenue outlook to $270–$273M

• Record Q3 revenue $72.7M, +19% YoY, driven by implants and OPSB growth.
• GAAP EPS loss improved to -$0.25 versus -$0.50 last year.
• Q3 2026 non-GAAP EPS was -$0.23, an improvement of 4% year over year.
• Company missed Q3 2026 EPS estimates but exceeded revenue estimates.
• Adjusted EBITDA reached record $6.9M, ~10% margin, reflecting strong operating leverage.
• Gross margin steady at 74% despite mix shift toward lower-margin but accretive OPSB.
• Free cash flow positive $1.6M versus -$3.4M prior year, guidance reiterated.
• 2026 revenue outlook raised to $270–$273M from $265–$269M, 14–16% growth; EBITDA ~$25M maintained.
• OPSB bracing grew above 20%, now over 60 clinics and 34 systems.
• International revenue rose 18% to $14.8M, led by EMEA; LatAm constrained by set discipline.
• Super Cycle products early but ramping, with major contributions expected in 2027 and beyond.
• Main risks include clinic expansion costs, Brazil/LatAm set pullback, and lumpy 7D and set sales.
• Main concern is sustainability of growth and margin expansion amid clinic investments and cautious LatAm deployment.

Summit Midstream Corporation (SMC)

Summit Midstream Partners, LP priced its initial public offering (IPO) of 12.5 million common shares at $20.00 per share on September 27, 2012, and began trading on the New York Stock Exchange under the ticker symbol SMLP, later transitioning its corporate structure to Summit Midstream Corporation (NYSE: SMC). 

• Sector: Energy
• Industry: Oil & Gas Midstream
• Headquarters: Houston, Texas
• Full Time Employees: 296
• Current Ticker/Structure: SMC (Summit Midstream Corporation) following its corporate conversion to a C-corporation
• https://www.summitmidstream.com